Lenz Robert A. 4
4 · Neumora Therapeutics, Inc. · Filed Oct 11, 2024
Insider Transaction Report
Form 4
Lenz Robert A.
Head of R&D
Transactions
- Sale
Common Stock
2024-10-10$15.09/sh−8,260$124,603→ 314,706 total - Sale
Common Stock
2024-10-09$15.01/sh−5,563$83,507→ 322,966 total
Footnotes (3)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024.
- [F2]This transaction was executed in multiple trades in prices ranging from $15.00 to $15.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $15.00 to 15.2435, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.